Labour Induction With Misoprostol, Dinoprostone and Bard Catheter (LI)

This study has been completed.
Information provided by:
Karolinska University Hospital Identifier:
First received: January 2, 2008
Last updated: January 15, 2008
Last verified: January 2008

This is a randomised study aimed at comparing the currently most frequently used prostaglandin dinoprostone to two other methods, the cheaper and perhaps more effective prostaglandin misoprostol and a transcervical catheter. 592 women were recruited and randomised to one of the three methods. The main outcome measures were time to delivery, rate of instrumental deliveries and maternal neonatal outcome. Our hypothesis was that misoprostol would be superior to the other methods.

The main finding of our trial was that the catheter showed the shortest induction to delivery interval. There were no differences between the two other prostaglandins. No differences in maternal and neonatal outcome was found

Condition Intervention Phase
Drug: misoprostol
Drug: dinoprostone
Device: Bard Catheter (balloon catheter)
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomised Comparison Between Intravaginal Dinoprostone Intravaginal Misoprostol and Transcervical Balloon Catheter for Labour Induction

Resource links provided by NLM:

Further study details as provided by Karolinska University Hospital:

Primary Outcome Measures:
  • Time from treatment start to delivery [ Time Frame: At delivery ] [ Designated as safety issue: No ]

Enrollment: 592
Study Start Date: December 2004
Study Completion Date: March 2007
Primary Completion Date: March 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Labour induction with misoprostol
Drug: misoprostol
0.025mg tablet vaginally every 4 hour until progress
Other Name: Cytotec, one quarter of a 0.100mg tablet
Active Comparator: 2
Labour induction with dinoprostone
Drug: dinoprostone
2mg vaginal gel every 6 hours until progress
Other Name: Minprostin
Experimental: 3
Labour induction with bard
Device: Bard Catheter (balloon catheter)
Intracervical balloon catheter positioned above internal cervical os and filled with sterile water. Removed when cervix was dilated
Other Name: Bard Catheter


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Full term singleton pregnancy with vertex presentation and with an indication for labour induction.
  • Absence of active labour
  • Bishop score ≤ 6.
  • Normal CTG registration

Exclusion Criteria:

  • Previous cesarean section
  • signs of infection
  • immediate need for delivery
  • any contraindication for vaginal delivery
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00602095

Sponsors and Collaborators
Karolinska University Hospital
Principal Investigator: Lena Marions, MD PhD Karolinska University Hospital Institute
  More Information

No publications provided

Responsible Party: Lena Marions MD PhD, Karolinska University Hospital Identifier: NCT00602095     History of Changes
Other Study ID Numbers: LMS2007, KS2007
Study First Received: January 2, 2008
Last Updated: January 15, 2008
Health Authority: Sweden: Regional Ethical Review Board

Keywords provided by Karolinska University Hospital:
Labor induction
cervical ripening
balloon catheter

Additional relevant MeSH terms:
Abortifacient Agents
Abortifacient Agents, Nonsteroidal
Anti-Ulcer Agents
Gastrointestinal Agents
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Therapeutic Uses processed this record on November 25, 2015